GlassScriptPhysician profile
Alexi Feiner Child
NPI 1780257329
$1,774.27
in general payments reported to CMS, 2019-2025
15 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $608 · 2023: $624 · 2024: $400 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $375.80 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Organon LLC | $310.52 | 2022-2024 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $172.70 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $122.82 | 2025 | |
| Avion Pharmaceuticals | $118.61 | 2022-2023 | Balcoltra |
| Mayne Pharma Commercial LLC | $117.03 | 2023 | |
| Novo Nordisk INC | $113.85 | 2023 | Novoseven |
| Amgen INC. | $109.97 | 2024 | Krystexxa |
| Exeltis, USA INC. | $101.19 | 2022-2024 | Slynd |
| Sumitomo Pharma America, INC. | $71.59 | 2024 | Myfembree, Gemtesa |
| Abbvie INC. | $46.76 | 2022 | |
| Pfizer INC. | $46.47 | 2023 | |
| Myovant Sciences INC. | $24.93 | 2022 | |
| Astellas Pharma US INC | $21.39 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $20.64 | 2023 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexi Child listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.